• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
  • Member Portal
  • Find a Nephrologist
IgA Nephropathy Foundation Logo
  • IgA Nephropathy Foundation Logo
  • About Us
        • MM About

          • About Us
          • Leadership Team
          • Board of Directors
          • Medical & Scientific Advisory Board
          • IgAN Go Global Network
        • MM About 2

          • Latest News, Media, and Tips
          • Our Partners
          • IgAN Ambassadors
          • Join The Newsletter
  • Events
        • Events

          • Calendar of Events
          • SPARK 2025
          • IgA Nephropathy Day
          • Rare Disease Day
  • Resources
        • MM – Resource 1

          • What is IgAN
          • Diagnosis
          • Understanding Your Lab Results
          • Understanding Your Biopsy
          • Understanding blood pressure and your kidneys
          • Treatment Options
        • MM – Resource 2

          • IgAN Info
          • Faces of IgAN
          • IgAN Risk Quiz
          • AAPI Higher Risk
          • IgAN Cookbook
          • IgAN FAQs
        • MM – Resource 3

          • Support Options
          • Patient Aid
          • IgANCare Program
          • Learn About Insurance
          • Patient + Care Partner Support
          • The IgA Nephropathy Foundation Ambassador Program
          • Caregiver Resources
          • Pregnancy and Family Planning
        • MM – Resource 4

          • Learning & Resources
          • IgAN+ App
          • Tools & Resources
          • Mental Health
          • Podcasts
          • IgAN Nutrition
          • IgAN Recipes
  • Research
        • MM Research

          • IgA Nephropathy Studies
          • IgA Nephropathy Research
          • Published Research Articles
        • MM Research 2

          • Clinical Trials
          • Considering a Clinical Trial?
          • View All Clinical Trials
  • Join
        • MM – Join 1

          • Become a Member
          • The IgA Nephropathy Foundation Ambassador Program
          • Ways to Give
          • Advocacy for IgAN
        • MM – Join 2

          • Join Our Newsletter
          • Patient Registry
  • Donate
  • IgANCare Program

News & Media

Building community following a rare kidney disease diagnosis: Ruchi’s story

May 13, 2025

Patient Voice spoke with Ruchi Ambike about her search to find community after being diagnosed with a rare disease.  “I had just started my master’s program in 2001 when a …

Category: News & Media
Read moreBuilding community following a rare kidney disease diagnosis: Ruchi’s story

IgA Nephropathy Foundation Announces the Launch of Go Global Network to Support for IgA Nephropathy Patients Worldwide

April 21, 2025

Expanding Global Support: IgA Nephropathy Foundation Launches Go Global Network to Connect and Empower IgAN Patients Worldwide. By expanding our network to Canada, we are building a stronger, more connected …

Category: News & Media
Read moreIgA Nephropathy Foundation Announces the Launch of Go Global Network to Support for IgA Nephropathy Patients Worldwide

IgA Nephropathy Foundation Celebrates 20 Years of Advocacy, Research, and Patient Support

March 18, 2025

WALL TOWNSHIP, NJ, UNITED STATES, March 18, 2025 /EINPresswire.com/ — The IgA Nephropathy (IgAN) Foundation marks its 20th anniversary in 2024, celebrating two decades of groundbreaking efforts in research, patient advocacy, and …

Category: News & Media
Read moreIgA Nephropathy Foundation Celebrates 20 Years of Advocacy, Research, and Patient Support

Travere and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgAN

February 23, 2024

SAN DIEGO, Feb. 23, 2024 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor today announced that the European Medicines Agency’s (EMA) CHMP has recommended approval of sparsentan for the treatment …

Category: News & MediaTag: IgA Nephropathy, igan treatment, iganephropathy
Read moreTravere and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgAN

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)

December 21, 2023

Ad hoc announcement pursuant to Art. 53 LR Read full press release here

Category: News & Media
Read moreNovartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)

Calliditas Therapeutics announces full FDA approval of TARPEYO®

December 20, 2023

On December 20, 2023, TARPEYO received full FDA approval for the new indication to reduce the loss of kidney function in adults with IgA Nephropathy (IgAN) who are at risk …

Category: News & Media
Read moreCalliditas Therapeutics announces full FDA approval of TARPEYO®

Improving Patient-Provider Communications in IgA Nephropathy.

October 27, 2023

We want to tell you about an important research collaboration between IgA Nephropathy Foundation and the National Kidney Foundation (NKF). This research will have two phases. First, separate surveys of …

Category: News & MediaTag: IgA Nephropathy
Read moreImproving Patient-Provider Communications in IgA Nephropathy.

IgAN Cookbook and Aware Day Press Release

May 12, 2023

The IgA Nephropathy Foundation Launches First-Ever Cookbook Ahead of IgAN Awareness Day The Second Annual ‘IgAN Aware Day’ brings attention to the need for earlier diagnosis and treatments; cookbook offers …

Category: News & Media
Read moreIgAN Cookbook and Aware Day Press Release

IgA Nephropathy Foundation Announces Launch of Medical and Scientific Advisory Board

May 25, 2022

May 25, 2022 – The IgA Nephropathy Foundation (IGAN Foundation), a nonprofit dedicated to supporting patients with a rare autoimmune kidney disease called IgA Nephropathy, today announced its formation of …

Category: News & Media
Read moreIgA Nephropathy Foundation Announces Launch of Medical and Scientific Advisory Board

Igan Basics

February 17, 2021

There is a lot of technical language around IgAN and it can seem confusing and overwhelming when receiving a diagnosis for yourself or a loved one. You may have many …

Category: News & Media
Read moreIgan Basics

National Kidney Foundation’s and IgA Nephropathy Foundation’s Externally-Led Patient Focused Drug Development (EL-PFDD) Meeting on IgA Nephropathy

January 16, 2021

The NKF and IGANF conducted an EL-PFDD meeting on IgAN to inform the FDA on the patient perspective on living with this disease. Understanding the patient perspective will help the …

Category: News & Media
Read moreNational Kidney Foundation’s and IgA Nephropathy Foundation’s Externally-Led Patient Focused Drug Development (EL-PFDD) Meeting on IgA Nephropathy

Ten Years Follow-up of STOP-IgAN Trial

June 5, 2020

Abstract The randomized, controlled STOP-IgAN trial in patients with IgA nephropathy (IgAN) and substantial proteinuria showed no benefit of immunosuppression added on top of supportive care on renal function over …

Category: News & Media
Read moreTen Years Follow-up of STOP-IgAN Trial
  • Page 1
  • Page 2
  • Next
Donate
  • Facebook
  • Twitter
  • Instagram
  • YouTube

Quick Links

  • About Us
  • Financials
  • Patient Resources
  • Research
  • Contact Us
  • Join Our Efforts
  • Privacy Policy

Contact Us

(848) 298-4618

PO Box 1322 Wall, NJ 07719

© 2025 All Rights Reserved.

IgAN Foundation Newsletter

Subscribe to our newsletter below!

First Name
Last Name
Enter your email address

No thanks, I’m not interested!

References

  • Hall, Y.N., Fuentes, E.F., Chertow, G.M. et al. Race/ethnicity and disease severity in IgA nephropathy. BMC Nephrol 5, 10 (2004). https://doi.org/10.1186/1471-2369-5-10
  • Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, et al. (2012) Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis. PLoS Genet 8(6): e1002765. doi:10.1371/journal.pgen.1002765